Vassilev, Lyubomir T.

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy

Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences

Cancer-related Molecular PathwaysHeat shock proteins research

Cited by 708

Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization

Graves, B., Thompson, T., Xia, M., Janson, C., Lukacs, C., Deo, D., Di Lello, P., Fry, D., Garvie, C., Huang, K.-S., et al. (2012) · Proceedings of the National Academy of Sciences

Cancer-related Molecular PathwaysHeat shock proteins research

Cited by 230

Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1

Ambrosini, G., Sambol, E. B., Carvajal, D., Vassilev, L. T., Singer, S., & Schwartz, G. K. (2007) · Oncogene

Cancer-related Molecular PathwaysCell death mechanisms and regulation

Cited by 163

Induction of p53-Dependent Senescence by the MDM2 Antagonist Nutlin-3a in Mouse Cells of Fibroblast Origin

Efeyan, A., Ortega-Molina, A., Velasco-Miguel, S., Herranz, D., Vassilev, L. T., & Serrano, M. (2007) · Cancer Research

Cancer-related Molecular PathwaysTelomeres, Telomerase, and Senescence

Cited by 140

p21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation

Xia, M., Knezevic, D., & Vassilev, L. T. (2011) · Oncogene

Cancer-related Molecular PathwaysCell death mechanisms and regulation

Cited by 64